MANAGEMENT OF HYPERTENSION: NEW PERSPECTIVES
https://doi.org/10.18705/1607-419X-2013-19-4-280-289
Abstract
The paper reviews the data on the novel drugs and procedures for hypertension management. Several directions are discussed: 1) novel drugs including novel pharmacological classes and novel molecules with additional effects on blood pressure and metabolism; 2) novel procedures and novel devices including baroreceptor stimulation and catheter renal sympathetic denervation
About the Authors
Zh. D. Kobalava
Russian People’s Friendship University, Moscow
Russian Federation
Russian Federation
Yu. V. Kotovskaya
Russian People’s Friendship University, Moscow
Russian Federation
Russian Federation
Corresponding author: Clinical Hospital № 64, the Department of Internal Diseases Propaedeutics at Russian People’s Friendship University, 61 Vavilov st., Moscow, Russia, 117292. E-mail: kotovskaya@bk.ru (Julia V. Kotovskaya, MD, PhD, Professor at the Department of Internal Diseases Propaedeutics at Russian People’s Friendship University).
S. V. Villevalde
Russian People’s Friendship University, Moscow
Russian Federation
Russian Federation
I. M. Amirbegishvili
Russian People’s Friendship University, Moscow
Russian Federation
Russian Federation
A. E. Solovyova
Russian People’s Friendship University, Moscow
Russian Federation
Russian Federation
References
1. Mancia G., de Backer G., Cifkova R. et al. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and of the European Society of Hypertension (ESH) // J. Hypertens. — 2007. — Vol. 25, № 6. — P. 1105–1187.
2. Kaplan N.M. Resistant hypertension // J. Hypertens. — 2005. — Vol. 23, № 8. — P. 1441–1444.
3. Esler M., Lambert E., Schlaich M. Point: chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension // J. Appl. Physiol. — 2010. — Vol. 109, № 6. — P. 1996–1998.
4. Dive V., Chang C.F., Yiotakis A., Sturrock E.D. Inhibition of zinc metallopeptidases in cardiovascular disease-from unity to trinity, or duality? // Curr. Pharm. Des. — 2009. — Vol. 15, № 31. — P. 3606–3621.
5. Corti R., Burnett J.C. Jr, Rouleau J.L., Ruschitzka F., Luscher T.F. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? // Circulation. — 2001. — Vol. 104, № 15. — P. 1856–1862.
6. Kosoglou T., Herron J.M., Chen R., Given B., Sybertz E.J., Affrime M.B. Antihypertensive effect of the atriopeptidase inhibitor SCH 34826 in essential hypertension // Circulation. — 1990. —Vol. 82. — P. 2201.
7. Laurent S., Boutouyrie P., Azizi M. et al. Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and ACE, in rats and humans // Hypertension. — 2000. — Vol. 35, № 5. —P. 1148–1153.
8. Weber M.A. Vasopeptidase inhibitors // Lancet. — 2001. —Vol. 358, № 9292. — P. 1525–1532.
9. Kostis J.B., Packer M., Black H.R., Schmieder R., Henry D.,Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs Enalapril (OCTAVE) trial // Am. J. Hypertens. — 2004. — Vol. 17, № 2. — P. 103–111.
10. Adam A., Cugno M., Molinaro G., Perez M., Lepage Y.,Agostoni A. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors // Lancet. — 2002. — Vol. 359,№ 9323. — P. 2088–2089.
11. Fryer R.M., Segreti J., Banfor P.N. et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema // Br. J. Pharmacol. — 2008. — Vol. 153, № 5. — P. 947–955.
12. Azizi M., Bissery A., Peyrard S. et al. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans // Clin. Pharmacol. Ther. — 2006. — Vol. 79, № 1. —P. 49–61.
13. Kalk P., Sharkovska Y., Kashina E. et al. Endothelin converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner // Hypertension. — 2011. — Vol. 57, № 4. —P. 755–763.
14. Gu J., Noe A., Chandra P., Al-Fayoumi S. et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) // J. Clin. Pharmacol. — 2010. — Vol. 50, № 4. — P. 401–414.
15. Ruilope L.M., Dukat A., Bohm M., Lacourciere Y., Gong J.,Lefkowitz M.P. Blood pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study // Lancet. — 2010. — Vol. 375, № 9722. — P. 1255–1266.
16. Grossmann C., Gekle M. New aspects of rapid aldosterone signaling // Mol. Cell Endocrinol. — 2009. — Vol. 308, № 1–2. —P. 53–62.
17. Amar L., Azizi M., Menard J., Peyrard S., Watson C.,Plouin P.F. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism // Hypertension. — 2010. — Vol. 56, № 5. — P. 831–838.
18. Calhoun D.A., White W.B., Krum H. et al. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial // Circulation. — 2011. — Vol. 124, № 18. — P. 1945–1955.
19. Weber M.A. Treatment of patients with hypertension and arthritis pain: new concepts // Am. J. Med. — 2009. — Vol. 122,№ 5, Suppl. — P. S16–S22.
20. Murca T.M., Almeida T.C., Raizada M.K., Ferreira A.J. Chronic activation of endogenous angiotensin-converting enzyme 2 protects diabetic rats from cardiovascular autonomic dysfunction // Exp. Physiol. — 2012. — Vol. 97, № 6. — P. 699–709.
21. Bodineau L., Frugiere A., Marc Y. et al. Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension // Hypertension. — 2008. — Vol. 51,№ 5. — P. 1318–1325.
22. Tissot A.C., Maurer P., Nussberger J. et al. Effect of immunization against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study // Lancet. — 2008. — Vol. 371, № 9615. —P. 821–827.
23. Nilsson P., Boutouyrie P., Laurent S. Vascular aging: a tale of EVA and ADAM in cardiovascular risk assessment and prevention // Hypertension. — 2009. — Vol. 54, № 1. — P. 3–10.
24. Kass D.A., Shapiro E.P., Kawaguchi M. et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker // Circulation. — 2001. — Vol. 104, № 13. — P. 1464–1470.
25. Peet M.M. Results of supradiaphragmatic splanchnicectomy for arterial hypertension // N. Engl. J. Med. — 1947. — Vol. 236, № 8. — P. 270–277.
26. Schwartz S.I., Grifith L.S.C., Neistadt A., Hagfors N. Chronic carotid sinus nerve stimulation in treatment of essential hypertension // Am. J. Surg. — 1967. — Vol. 114, № 1. — P. 5–15.
27. Elliott W.J., Izzo J.L. Jr, White W.B. et al. Graded blood pressure reduction in hypertensive outpatients associated with use of a device to assist with slow breathing // J. Clin. Hypertens. — 2004. — Vol. 6, № 10. — P. 553–559.
28. Bradley T.D., Floras J.S. Obstructive sleep apnoea and its cardiovascular consequences // Lancet. — 2009. — Vol. 373, № 9657. — P. 82–93.
29. Green A.L., Wang S., Bittar R.G. et al. Deep brain stimulation: a new treatment for hypertension? // J. Clin. Neurosci. — 2007. — Vol. 14, № 6. — P. 592–595.
30. Illig K.A., Levy M., Sanchez L. et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial // J. Vasc. Surg. — 2006. — Vol. 44, № 6. — P. 1213–1218.
31. Naraghi R., Geiger H., Crnac J. et al. Posterior fossa-neurovascular anomalies in essential hypertension // Lancet. — 1994. Vol. 344, № 8935. — P. 466–470.
32. Krum H., Schlaich M.P., Whitbourn R. et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study // Lancet. — 2009. — Vol. 373, № 9671. — P. 1275–1281.
33. Sharma S.K., Agrawal S., Damodaran D. et al. CPAP for the metabolic syndrome inpatients with obstructive sleep apnea // N. Engl. J. Med. — 2011. — Vol. 365, № 24. — P. 2277–2286.
34. Pepperell J.C.T., Ramdassingh-Dow S., Crosthwaite N. et al. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomized parallel trial // Lancet. — 2001. — Vol. 359, № 9302. — P. 204–210.
35. Lozano L., Tovar J.L., Sampol G. et al. Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial // J. Hypertens. — 2010. — Vol. 28, № 10. — P. 2161–2168.
36. Carter H.H., Dawson E.A., Cable T. et al. Deep brain stimulation of the periaqueductal grey induces vasodilatation in humans // Hypertension. — 2011. — Vol. 57, № 5. — P. e24–e25.
37. Altena M.R., Kleefstra N., Logtenberg S.J., Groenier K.H., Houweling S.T., Bilo H.J. Effect of device-guided breathing exercises on blood pressure in patients with hypertension // Blood Pressure. — 2009. — Vol. 18, № 5. — P. 273–279.
38. Dampney R.A., Horiuchi J. Functional organization of central cardiovascular pathways: studies using c-fos gene expression // Prog. Neurobiol. — 2003. — Vol. 71, № 5. — P. 359–384.
39. Sasaki S., Tanda S., Hatta T. et al. Neurovascular decompression of the rostral ventrolateral medulla decreases blood pressure and sympathetic nerve activity in patients with refractory hypertension // J. Clin. Hypertens. — 2011. — Vol. 13, № 11. — P. 818–820.
40. Lohmeier T.E., Iliescu R., Boshen L., Henegar J.R., Maric-Bilkan C., Irwin E.D. Systemic and renal-specificsympathoinhibition in obesity hypertension // Hypertension. —2012. — Vol. 59, № 2. — P. 331–338.
41. Heusser K., Tank J., Engeli S. et al. Carotid baroreceptor stimulation, sympathetic activity, barorelex function and blood pressure in hypertensive patients // Hypertension. — 2010. — Vol. 55, № 3. — P. 619–626.
42. Bisognano J.D., Bakris G., Nadim M.K. et al. Barorelex activation therapy lowers blood pressure in patients with resistant hypertension // J. Am. Coll. Cardiol. — 2011. — Vol. 58, № 7. — P. 765–773.
43. Sanchez L.A., Illig K., Levy M. et al. Implantable carotid sinus stimulator for the treatment of resistant hypertension // Ann. Vasc. Surg. — 2010. — Vol. 24, № 2. — P. 178–184.
44. Esler M.D., Krum H., Sobotka P.A., Schlaich M.P., Schmieder R.E., Bohn M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial // Lancet. — 2010. — Vol. 376, № 9756. — P. 1903–1909.
45. Atherton D.S., Deep N.L., Mendelsohn F.O. Micro-anatomy of the renal sympathetic nervous system: a human postmortem biologic study // Clin. Anat. — 2012. — Vol. 25, № 5. — P. 628–633.
Review
For citations:
Kobalava Zh.D., Kotovskaya Yu.V., Villevalde S.V., Amirbegishvili I.M., Solovyova A.E. MANAGEMENT OF HYPERTENSION: NEW PERSPECTIVES. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2013;19(4):280-289. (In Russ.) https://doi.org/10.18705/1607-419X-2013-19-4-280-289
Views:
1588
Email this article 